| | | Friday, December 4, 2015 | Issue #2689 | |
|
Urgent: FREE Oxford Club Summit (Your Complimentary Invitation)
A new way of attacking deadly Superbugs is emerging thanks to a shocking medical breakthrough that Harvard doctors report, "Could hold the keys to improving life." It's called the Microbiome Revolution, and it's also creating one of the biggest investing opportunities we may see in our lifetimes.
That's why The Oxford Club has assembled a team of investing and health experts to present our FREE Online Summit, "SuperBugs, SuperCures, SuperProfits: How to Make a Fortune from the $230 Billion Microbiome Revolution". On it, we'll give you everything you need to know so you can profit from the megatrend that's right around the corner… and stay healthier too.
Claim your spot (for FREE) by clicking here. | |
|
Investing in the New Era of Medicine Marc Lichtenfeld, Chief Income Strategist, The Oxford Club
It's easy to get excited by the amazing breakthroughs in medicine these days.
It seems like every day there's word of an innovative new drug to treat cancer... either by targeting a specific genetic mutation or sparking the immune system into action.
There are incredible new tests that enable patients to skip painful and unnecessary biopsies. And new therapies for heart conditions... diabetes... cystic fibrosis...
You name it, doctors are working on it. In many cases, they are coming up with life-changing breakthroughs.
One area that has investors most excited - and hopeful - is in genetics and DNA sequencing. It is believed that in the not-too-distant future nearly every cancer patient will have the DNA from his or her tumor sequenced.
This will add tons of data to cancer research, as well as shed light on undiscovered genetic mutations and their roles in a variety of cancers.
And not just cancer...
Soon, all kinds of health data will be collected by your doctors - both in-office and via your own smart devices. Not only will you know the specific disease causing genetic mutations you have... you'll also see how your blood sugar spiked after eating a donut.
THE END OF PETROLEUM?
 A little-known overseas company will soon fuel more than 10 million U.S. cars per year... without using petroleum.
Yet it's not a pipe dream like solar, hydro, wind, corn, algae or anything else you are probably thinking.
This miracle of science will surprise you... and could make first-in investors very rich.
Discover this little-known company's "Mircle of Science"... (before it becomes front-page news). | |
I recently attended a conference on genome sequencing. One of the big themes was data. There is a lot available right now - and more is discovered every day.
Yet patients often have the least access to their own health data. And if they can get it, the data is incredibly hard to decipher.
We are not far away from apps or other tools that will interpret gigabytes' worth of your health data for you.
But there are a few problems that need to be addressed before we enter this utopian healthcare world where all the data you need is available to be interpreted and put to use.
First, we have lots of information - but not a lot of knowledge. If you have your genome sequenced and find you are at risk for a specific disease due to a mutation, in most cases there isn't a lot you can do about it.
Get screened early. Eat right and exercise. These are the likely recommendations of your doctor. And you know what they will tell you if you don't have a mutation? Get screened early (maybe). Eat right and exercise.
The other big issue here is privacy. At the conference, this idea was brushed "There is a lot of data available right now - and more is discovered every day.
"Yet patients often have the least access to their own health data. And if they can get it, the data is incredibly hard to decipher." | |
|
aside with the logic that you won't share your data with anyone you don't want to. But keep in mind that the people making those statements have, for the most part, drank the Kool-Aid when it comes to sequencing the genome and all of the amazing things that come with it.
I don't mean that in a derogatory way. These are brilliant scientists who are passionate and excited about the coming advances. But in order for this progress to happen, lots and lots of data needs to be exchanged.
During a panel discussion, I nearly brought the conference to a screeching halt when I asked about the role of insurance and the likelihood of having to pay higher life insurance premiums if a person is found to have a mutation linked to cancer...
Or higher premiums on long-term care insurance if a certain variant of the APOE gene is found, which is linked to Alzheimer's.
While no one feels sorry for insurance companies, it is a valid argument to say that if a person has information like that on themselves and the insurance company doesn't, it is not a level playing field. Even worse, people could game the system and drive the insurers out of business.
In other words, there is a lot of regulatory work to be done when it comes to privacy, insurance and security. Until that happens, I have a hard time picturing the widespread sharing of health data, even if it would result in better science.
We're on the threshold of a new era in medicine. One that could see horrible diseases eradicated... or become chronic conditions rather than fatal (like HIV). But the technology and the complicated issues that go along with it have to be dealt with. Otherwise, it could create a wide range of problems that we're not equipped to deal with.
Next month, I will attend the J.P. Morgan Healthcare Conference, which is the biggest healthcare investing conference of the year. Well over 10,000 people descend on San Francisco to meet with CEOs, scientists, policy makers, bankers, traders and analysts to get the latest on advances in medicine.
I will follow up on this important subject when I get back. Stay tuned.
Good investing,
Marc
P.S. If you're as fascinated by the healthcare sector as I am - or at least interested in profiting from all of the coming advances - then you should know that I'll be participating in a FREE online summit on December 9.
At this special event, I'll join renowned gastroenterologist and assistant professor at Georgetown University Hospital Dr. Robynne Chutkan, as well as Jenny Thompson, director of the Health Sciences Institute. The three of us will discuss an amazing new class of drugs and treatments... and the companies that are poised to soar as government money pours into them.
It's a dream opportunity for investors, poised to take off starting just weeks from now. To see more details and register for FREE, simply click here.
| |
|
The Best-Selling Drugs in the World
Genetic Engineer & Biotechnology News recently released a list of the best-selling drugs in the world.
On the list were just 25 little pills... you could fit them all in the palm of your hand... yet they accounted for $145 BILLION in revenue.
But there's one particular treatment on this list that offers a complete, 100% medical cure.
Click here to see what could soon become the best-selling drug of ALL TIME. | |
|
| |
With government hurdles, patent disputes and heavy competition, the healthcare sector can be intimidating. That's why, today, Investment U Plus readers are discovering a strong biotech play with plenty of cash and lots of room for growth. To find out how you can get all the details, click here. | |
|
| |
The 2016 presidential contest will be one of the most consequential elections in modern history. But it isn't Obama's legacy that has folks flocking toward Trump. Read On... | |
|
| |
In February, the New York Stock Exchange will implement a new rule that is sure to affect many investors. Marc laid out some of the details in Investment U last week. But he had some additional thoughts in Monday's episode of Oxford Club Radio. Read On... | |
|
|
|
No comments:
Post a Comment
Keep a civil tongue.